Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Randomized, Parallel Dose Group Study to Assess the Pharmacokinetics of Mirabegron OCAS Formulations With Different Release Rates Versus IV Infusion in Healthy Volunteers
Conditions
Interventions
mirabegron
mirabegron
Locations
1
United States
Tacoma, Washington, United States
Start Date
April 30, 2009
Primary Completion Date
July 13, 2009
Completion Date
July 13, 2009
Last Updated
October 16, 2024
NCT06716502
NCT07310264
NCT00090662
NCT06290258
NCT07483606
NCT06342713
Lead Sponsor
Astellas Pharma Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions